The White House confirmed Friday that it plans to install 25% tariffs on goods from Canada and Mexico—effective February ...
The head of the FDA’s artificial intelligence-focused Digital Center of Excellence, Troy Tazbaz, is departing the agency, ...
After spending years developing its endoscopic device treatment for patients with Type 2 diabetes, Fractyl Health is now ...
Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s ...
A sugar produced by soil bacteria may be able to stop the loss of skin pigment caused by vitiligo. | A sugar produced by ...
After leading Japan’s largest drugmaker for 11 years, Takeda CEO Christophe Weber plans to step down in June of 2026. He will ...
During a panel discussion at this year’s Fierce JPM Week—which took place alongside the annual J.P. | This week on “The Top ...
Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...
Kadimastem’s attempt to vault onto Nasdaq is picking up momentum, with shareholders signing off on a merger with NLS Pharmaceutics that would enable the cell therapy developer to recover from last ...
Eyeing an expected leap in demand for contrast media—used in X-rays, CT scans and more—GE HealthCare is upping its stake in the Emerald Isle. | GE HealthCare is pumping $138 million into its ...
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...